Corey J. Langer, MD, FACP: The REVEL trial identified a subgroup of early, rapid progressors on frontline therapy who seemed to derive an extraordinary benefit from the combination of docetaxel and ramucirumab. Of those enrolled in the study, roughly 11% or so had progression on their frontline regimen within 9 weeks, 17% within 12 weeks, and 28% or so within 20 weeks or so. That group had a greater relative benefit with respect to survival than the overall population. The hazard ratio for the earliest progressors was 0.69. It was 0.74 for the 12-week group and, ultimately, about 0.80 for the group who had disease progression on the frontline regimen at about 20 weeks. The group included all-comers.
The overall trial showed about a 3-month difference in median survival, favoring the combination of docetaxel and ramucirumab compared with docetaxel alone. It was about 12, 12.5 months versus 9 months or so. As you’d expect, this is a more refractory group—probably worse protoplasm, worse pathology. So, the numbers are lower, but the relative benefit is more on the order of 3.5 to 4 months, or from 4 to 5 months up to about 9 months or so. So, again, this becomes a very attractive regimen for patients whose disease has progressed quickly on frontline treatment.
I’ve seen patients with rapid progression. With docetaxel alone, response rates are fairly poor—3% to 8% or maybe 10% at best. In combination with ramucirumab, those response rates more than double—18% to 20%, sometimes higher. The progression-free survival and overall survival benefit is clear-cut, so this is a group I will preferentially treat with ramucirumab and docetaxel. But I’d certainly be open to other ramucirumab combinations. I don’t think we necessarily should be wedded to docetaxel, and that’s an area that’s ripe for clinical investigation.
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen